Sputum vitamin D binding protein: A potential biomarker of airway vitamin D axis in asthma

In-silico identification and prioritization of therapeutic targets of asthma

Asthma is a "common chronic disorder that affects the lungs causing variable and recurring symptoms like repeated episodes of wheezing, breathlessness, chest tightness and underlying inflammation. The interaction of these features of asthma determines the clinical manifestations and severity of asthma and the response to treatment" [cited from: National Heart, Lung, and Blood Institute. Expert Panel 3 Report. Guidelines for the Diagnosis and Management of Asthma 2007 (EPR-3). Available at: https://www.ncbi.nlm.nih.gov/books/NBK7232/ (accessed on January 3, 2023)]. As per the WHO, 262 million people were affected by asthma in 2019 that leads to 455,000 deaths ( https://www.who.int/news-room/fact-sheets/detail/asthma ). In this current study, our aim was to evaluate thousands of scientific documents and asthma associated omics datasets to identify the most crucial therapeutic target for experimental validation. We leveraged the proprietary tool Ontosight® Discover to annotate asthma associated genes and proteins. Additionally, we also collected and evaluated asthma related patient datasets through bioinformatics and machine learning based approaches to identify most suitable targets. Identified targets were further evaluated based on the various biological parameters to scrutinize their candidature for the ideal therapeutic target. We identified 7237 molecular targets from published scientific documents, 2932 targets from genomic structured databases and 7690 dysregulated genes from the transcriptomics and 560 targets from genomics mutational analysis. In total, 18,419 targets from all the desperate sources were analyzed and evaluated though our approach to identify most promising targets in asthma. Our study revealed IL-13 as one of the most important targets for asthma with approved drugs on the market currently. TNF, VEGFA and IL-18 were the other top targets identified to be explored for therapeutic benefit in asthma but need further clinical testing. HMOX1, ITGAM, DDX58, SFTPD and ADAM17 were the top novel targets identified for asthma which needs to be validated experimentally.

FEF25-75% Is a More Sensitive Measure Reflecting Airway Dysfunction in Patients with Asthma: A Comparison Study Using FEF25-75% and FEV1

BACKGROUND

Reduced forced expiratory flow between 25% and 75% of vital capacity percent predicted (FEF_25-75%) representing small airway dysfunction (SAD) was associated with asthma development and progression.

OBJECTIVE

To investigate whether FEF_25-75% was superior to forced expiratory volume in 1 second in predicted (FEV₁%) in reflecting asthma features in adult patients.

METHODS

A retrospective spirometry dataset comprising 1801 adult patients with confirmed asthma and a subgroup of 332 patients having detailed clinical data were used to explore the association of FEF_25-75% and/or FEV₁% with clinical features of asthma.

RESULTS

Of the 1801 subjects, FEV₁% and FEF_25-75% ranged from 136.8% to 10.2% and 127.3% to 3.1%, respectively. FEF_25-75% < 65% was present in 1,478 (82.07%) of patients. FEF_25-75% was strongly correlated with matched FEV₁% (r = 0.900, P < .001). FEF_25-75% and FEV₁% were both correlated with airway hyperresponsiveness (r = 0.436, P < .001; r = 0.367, P < .001), asthma control test score (r = 0.329, P < .001; r = 0.335, P < .001), and sputum eosinophil count (r = -0.306, P < .001; r = -0.307, P < .001). Receiver-operating characteristic curves showed that FEF_25-75% had greater value in predicting severe asthma (area under the curve: 0.84 vs 0.81, P = .018), airflow obstruction (0.97 vs 0.89, P < .001), and severe bronchial hyperresponsiveness (0.74 vs 0.69, P = .012) as compared with FEV₁%. Patients with SAD (FEF_25-75% < 65%) in the presence of normal FEV₁% exhibited higher sputum eosinophil counts and had an increased dosage of daily inhaled corticosteroids (P < .001 and P = .010) than patients with normal lung function and their FEF_25-75% values correlated with sputum eosinophil count (r = -0.419, P = .015), but not FEV₁%.

CONCLUSION

FEF_25-75% represented small airway function and was more sensitive at reflecting airway hyperresponsiveness, inflammation, and disease severity as compared with FEV₁% in patients with asthma. Our data suggest further assessment of FEF_25-75% in asthma management, particularly for those with SAD who present normal FEV₁%.